论文部分内容阅读
目的观察血清脂蛋白-α在阿托伐他汀钙治疗心脑血管疾病中的变化。方法 200例心脑血管患者作为试验组,按照疾病种类分为冠心病组40例,高血压组45例,脑血管疾病组35例,高血压冠心病组42例,心肌梗死组38例。另外选取40例在我院体检正常的健康成人作为对照组。入院后检测所有研究对象的氧化低密度脂蛋白(OXLDL)胆固醇、一氧化氮(NO)、血清脂蛋白-α水平,并对各组结果分别进行比较分析。然后给予心脑血管疾病患者阿托伐他汀钙20 mg·d~(-1),3个月为1个疗程。治疗后,对患者进行相同检测,将检测结果与对照组进行比较。结果治疗前,各组患者的氧化低密度脂蛋白、一氧化氮、血清脂蛋白-α水平与对照组比较,差异有统计学意义(P<0.05)。治疗后,各组患者的氧化低密度脂蛋白胆固醇、一氧化氮、血清脂蛋白-α水平与治疗前相比明显改善,与治疗前相比,差异有统计学意义(P<0.05);与对照组比较,差异无统计学意义(P>0.05)。阿托伐他汀钙治疗心脑血管疾病患者的总有效率为68.0%,效果良好。结论血清脂蛋白-α可用于评价阿托伐他汀钙治疗心脑血管疾病的临床疗效。
Objective To observe the changes of serum lipoprotein-α in atorvastatin calcium treatment of cardiovascular and cerebrovascular diseases. Methods A total of 200 patients with cardiovascular and cerebrovascular diseases were included in the study. The patients were divided into coronary heart disease group (40 cases), hypertension group (45 cases), cerebrovascular disease group (35 cases), hypertension and coronary heart disease group (42 cases) and myocardial infarction group (38 cases). In addition, 40 healthy adults who were normal physical examination in our hospital were selected as the control group. After admission, all subjects were tested for the levels of oxidized low density lipoprotein (OXLDL), nitric oxide (NO) and serum lipoprotein-α, and the results of each group were compared and analyzed. Then given atorvastatin calcium 20 mg · d ~ (-1) in patients with cardiovascular and cerebrovascular diseases, 3 months for a course of treatment. After treatment, the same test was performed on the patients and the test results were compared with the control group. Results Before treatment, the levels of oxidized low density lipoprotein, nitric oxide and serum lipoprotein-α in each group were significantly different from those in the control group (P <0.05). After treatment, the levels of oxidized low-density lipoprotein cholesterol, nitric oxide and serum lipoprotein-α in all groups were significantly improved compared with before treatment, and the difference was statistically significant (P <0.05); There was no significant difference in the control group (P> 0.05). Atorvastatin calcium treatment of cardiovascular and cerebrovascular disease patients with a total effective rate of 68.0%, the effect is good. Conclusion Serum lipoprotein-α can be used to evaluate the clinical efficacy of atorvastatin calcium in the treatment of cardiovascular and cerebrovascular diseases.